

GSK2656157

Catalog No: tcsc3262



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1337532-29-2

Formula:

$C_{23}H_{21}FN_6O$

Pathway:

Cell Cycle/DNA Damage

Target:

PERK

Purity / Grade:

>98%

Solubility:

DMSO : \geq 41 mg/mL (98.45 mM)

Observed Molecular Weight:

416.45


Product Description

GSK2656157 is an ATP-competitive inhibitor of **PERK** enzyme activity with an **IC₅₀** value of 0.9 nM, and highly selective for PERK with IC₅₀ values of > 100 nM against a panel of 300 kinases.

IC50 & Target: IC50: 0.9 nM (PERK)

In Vitro: GSK2656157 results in inhibition of PERK activation as well as decreases in the downstream substrates, phospho-eIF2 α , ATF4, and CHOP with an IC₅₀ in the range of 10-30 nM in the BxPC3 pancreatic tumor cell line. Cells that are exposed to 1 μ M GSK2656157 before UPR induction are able to block this effect on de novo protein synthesis^[1]. GSK2656157 causes the activation of another eIF2 α kinase to compensate for the loss of PERK activity in HT1080 cells. GSK2656157 inhibits the growth of the HT1080 cells^[2]. GSK2656157 inhibits LPS-induced IL-1 β production, LPS-induced Caspase 1 activation and LPS-induced eIF-2 α phosphorylation, but does not inhibit LPS-induced TNF- α production^[3].

In Vivo: GSK2656157 (1.5-150 mg/kg, p.o.) results in dose-dependent inhibition of phospho-PERK Thr980, with more than 80% inhibition at 50 and 150 mg/kg. GSK2656157 (50-150 mg/kg, p.o.) results in dose-dependent inhibition of tumor growth in human tumor xenograft models^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!